網頁

醫藥 - CABA 12/19

2020 SAPA-NE Career Development Webinar

 SAPA-NE 美中药协SAPA 

S

M

T

W

T

F

S


_


_

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31


_


_

2020

DECEMBER

2


活动时间:
2020年12月2日 8:00 PM - 9:00 PM 
(EDT, 美国东部时间)


请点击以下链接或扫描右侧二维码进行注册

https://www.sapa-neweb.org/2020stock_tax



_

美中医药开发协会新英格兰(SAPA-NE)将于2020年12月2日携手安永(EY),邀请行业专家为你详细讲述美国员工股权激励计划以及相关税务影响。


不管你是初入职场,创业达人,或者企业高管,员工股权激励计划都与你息息相关。当下,股权激励已经成为薪酬架构中非常重要的一部分。一方面,公司通过股权激励来吸引和保留人才,另一方面,员工有机会借助税务递延的优势实现财富的积累。然而越来越复杂的股权激励计划是否常常让你困惑?各种形式的股权激励计划到底是什么意思?在注定不平凡的2020年以及后疫情时代,如何更好的在员工股权计划中受益?我们邀请到安永的资深专家为大家剖析不同形式的股权激励计划,以及相关的公司或个人层面的美国税务影响。


_

演讲嘉宾 

Jason S French

Managing Director, People Advisory Services


Jason is a Managing Director in the People Advisory Services practice of EY, with 15 years of experience related to the analysis, design and implementation of compensation and benefit matters for both US domestic and internationally mobile employees. Jason’s areas of expertise are specifically within the compensation and benefits space for both US and multinational companies around the globe, equity compensation, global equity, golden parachutes, annual & long-term incentive plan and design, payroll and tax withholding, and US tax technical matters. Jason also advises companies on SEC Executive Compensation Proxy Disclosure rules and director compensation matters.


Claudia Timmermans

Senior Manager, People Advisory Services


Claudia has over 8 years of experience advising clients regarding (global) compensation and benefits arrangements. Claudia has significant experience on assisting clients with maximizing the benefits of equity compensation plans for mobile employee workforces, which includes advising clients on equity plan design and implementation, tax feasibility and due diligence, risk mitigation, global payroll transformation and employee education. She also advises clients on the implications of Internal Revenue Code Sections 162(m), 280G (golden parachutes), 409A, and 457A. 


点击阅读原文(Read More) 进入注册链接 

Read more
Reads 272

2020 CABA Boston BioForum Online

 Jo Lee CABA 

Boston

BioForum 

On


在疯狂的2020年压抑了太久,CABA Boston BioForum Online将于12月19日举行,为这不平凡的一年做个强势收官,总结COVID-19带来的危与机,预测生物医药投资趋势,并展望美中两个大经济体生物医药业的未来。会议邀请了数位行业大咖与大家齐聚线上,与您分享探讨2020年生物医药大事件!


Topics

热点话题

1

Chuan He, PhD, Professor, HHMI, University of Chicago

RNA Methylation in Human Diseases


Speaker Bio:

Dr. He is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular Biology at the University of Chicago. He received his bachelor of science degree in 1994 from the University of Science and Technology of China and his Ph.D. in chemistry from the Massachusetts Institute of Technology in 2000, studying under professor Stephen J. Lippard. After training as a Damon-Runyon postdoctoral fellow with professor Gregory L. Verdine at Harvard University, he joined the University of Chicago as an assistant professor, rising to associate professor in 2008 and full professor in 2010. He was selected as an investigator of the Howard Hughes Medical Institute in 2013. Dr. He’s research spans a broad range of fields including chemical biology, RNA biology, epigenetics, biochemistry, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. In 2011, his group discovered reversible RNA methylation as a new mechanism of gene expression regulation. His laboratory has spearheaded the development of enabling technologies to study the biology of RNA and DNA modifications.

2

Robert DeLuccia, 

Managing Partner and Founder, Acurx Pharmaceuticals

Acurx Developing a New Class of Antibiotics: Preparedness for the Next Infectious Disease Pandemic, Antimicrobial Resistance


Speaker Bio:

Bob DeLuccia has 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was most recently Executive Chairman of publicly-traded (NASDAQ) Dipexium Pharmaceuticals, Inc., a development-stage biopharmaceutical company based in New York City which he co-founded and subsequently took public. In April, 2017, Dipexium closed a merger with PLx Pharma Inc. (PLXP-NASDAQ), a late-stage specialty pharmaceutical company focused on developing AspertecTM, its aspirin product in its proprietary PLxGuardTM drug delivery system to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy and better tolerated treatment. He is currently Co-Founder and Managing Partner of Acurx Pharmaceuticals, a New York-based, development-stage biopharmaceutical company focused on developing a new class of antibiotics to treat common infections caused by certain Gram- positive bacteria and to combat the global crisis of antimicrobial resistance (AMR) to currently available antibiotics. He is also a member of the Board of Directors of IBEX Pharmaceuticals, a publicly- traded (IBT.V/TSXV.IBT), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use and arthritis assays widely used in osteoarthritis research. 

His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: amrinone, iohexol contrast media, clopidogrel. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection. 

Mr. DeLuccia received his undergraduate degree and MBA from Iona College, New York. Military Service, Officer, U.S. Army Corps of Engineers. 

3

Ricky Sun, PhD, Partner, Bain Capital Life Sciences

Life Science Investing, a Global Perspective



Speaker Bio:


Experience

Dr. Sun joined Bain Capital Life Sciences in 2016 and is a partner. He is currently a member of the Board of Directors of Arcutis (NASDAQ: ARQT), Annexon (NASDAQ: ANNX), and Savara (NASDAQ: SVRA). He is also a board observer of Pharvaris. Previously he also served as a board observer for Replimune (NASDAQ: REPL).

Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.


Education

Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.  He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar.  He graduated summa cum laude from Berea College with a BA in chemistry.

4

Chris Garbedian, CEO, Xontogeny

Venture Investment in Rare Diseases


Speaker Bio:


Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

5

Angus Grant, PhD, Chief Business Executive, BeiGene

Building Portfolio with Business Development Support for China



Speaker Bio:


Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant will oversee business development and alliance management, and help drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.


日期:2020年12月19日

时间:美东时间早上9点/中国时间晚上10点

Join Zoom Meeting


Meeting ID: 879 9988 3589

Passcode: 498231


按二维码参加会议


CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.


Chinese-American BioMedical Association


【预告】数字科技下的精准精神健康治疗|医路领航第四期

 哈佛中国健康协会 Harvard Healthcare Club 

本文共1841字,阅读约需6分钟



数字科技下的精准精神健康治疗

医路领航研讨会 第四期

在世界范围内,大约有七分之一的人曾患有精神健康疾病,而且这个比例还在持续增长。除了未满足的医疗需求外,精神健康疾病还会导致社会生产力下降约35%,人均预期寿命缩短10-25年,从而导致巨大的社会和经济负担。一方面,早期筛查和诊断以及进行早期干预治疗可以有效地延迟甚至预防疾病的发作,并最大程度地减少对患者和家庭造成的情感和经济损失。另一方面,从长远角度来看,持续的随访和治疗进展监测对于预防复发和提高患者的生活质量至关重要。但是,与当前护理模式中的疗法相比,预防和随访在很大程度上被忽略了


通过先进的人工智能算法和多模式大数据,数字化精神健康产品现在能够捕获个人的数字化生物标记物,从而在整个连续治疗过程中提供个性化护理,包括提供早期诊断、治疗建议以及进行持续的患者监测。


我们很荣幸地邀请到了两位来自数字化精神健康治疗领域的发展先驱公司的演讲嘉宾,与我们分享他们的公司愿景,以及他们对数字化精神健康治疗未来的看法:Paul Dagum博士(Mindstrong的创始人和前首席执行官),Sharief Taraman博士(Cognoa首席医务官。Cognoa专注于儿童神经发育障碍的治疗,例如自闭症和注意缺陷与多动障碍;Mindstrong关注对严重的精神障碍的治疗。


0

1

Dr. Paul Dagum



Mindstrong是一家医疗创新公司,以Mindstrong的创始人,副董事长兼首席科学官Paul Dagum博士的前瞻性研究作为基础。Mindstrong致力于通过数字化测量,利用数据科学和线上护理模型的创新来改变精神健康状态。

     


Mindstrong提供的解决方案和健康服务有助于在护理过程中抢得先机以改善治疗效果。他们得到了ARCH Venture Partners,General Catalyst,Foresite Capital,Optum Ventures,8VC等投资公司的支持。









 


Paul Dagum博士是Mindstrong的创始人,并在2019年11月前一直担任其首席执行官。他是一位企业家,也是医师和计算机科学家,他曾作为创始人、首席科学官、首席技术官和首席执行官,将产品、技术和商业模式的创新引入医疗健康、网络安全和供应链领域,并受到了多家知名风险投资公司的支持。Dagum博士对动态贝叶斯网络的早期研究已在许多现代应用中使用。他还开发了用于数据科学的大规模可扩展算法,应用于大量世界领先的数据公司,以及通过从移动设备被动捕获的人机交互中,创建了首个脑功能数字化量度技术,两者均获得了专利。同时,Dagum博士也在持续测量技术和人工智能赋能的远程医疗基础上,设计了用于精神健康的数字化护理模式。


Dagum博士在斯坦福大学期间领导了由美国国家科学基金会(NSF)和美国国立卫生研究院(NIH)资助的研究,发表了超过85篇在计算机科学和医学领域的同行评审文章和书籍章节,并获得了超过25项专利。Dagum博士获得了多伦多大学的理论物理学硕士学位和理论计算机科学博士学位,以及斯坦福大学的医学博士学位和外科住院医师培训。


0

2

Dr. Sharief Taraman



Cognoa是一家市场领先的专注于儿科行为健康的公司。Cognoa正在开发处方数字疗法,以更早地识别和治疗行为健康问题,从而改变护理标准,并改善会影响儿童终身的治疗效果。Cognoa的主要处方产品,包括首个针对自闭症的数字诊断技术和首个针对自闭症儿童的处方数字化疗法,均已获得FDA的突破性设备称号。 


该公司的AI技术平台还同时支持Cognoa的其他产品线,包括解决来自ADHD和焦虑症等其他未满足的临床需求。



 


医学博士Sharief Taraman获得了神经病学领域的双重认证,包括美国精神病学委员会的儿童神经病学和美国预防医学委员会的神经病学及临床信息学的专业资格认证。他是CHOC儿童专科学院的儿科神经病学系主任,也是加州大学欧文分校医学院的临床副教授


Taraman博士是儿科行为健康公司Cognoa的首席医务官,该公司的前两个处方数字化设备均获得了FDA突破性设备的称号,这两种设备旨在提高行为健康问题的早期治疗的护理标准。



活动安排


研讨会主题

数字科技下的精准精神健康治疗


主讲嘉宾

Mindstrong - Paul Dagum, MD, PhD

Cognoa - Sharief Taraman, MD


活动方式

Zoom 直播


活动时间

美东时间: 11月21日 8:00-9:00 pm

美西时间: 11月21日 5:00-6:00 pm

北京时间: 11月22日 9:00-10:00 am


报名链接

扫描下方二维码或点击“阅读原文”报名



审核通过后,将由邮件确认参会方式


活动鸣谢

统筹:茅傲岳 朱子溪 闫姿秀 王目阔 

王硕 王紫 戴钰

文字:闫姿秀

美编:王紫 朱霁清

特别感谢:盛开


医路领航研讨会

医路领航研讨会(Frontier Healthcare Cross Talk)以激励创新技术转化为目的,以研讨会为载体,邀请中美的顶级投资人、头部企业、优秀创业公司、及来自哈佛、MIT等的专家学者,帮助哈佛及友校的学生学者群体跟踪最实用的前沿医疗产业动态,协同中美医疗业界掌握最干货的前沿科学研究成果。通过定期跨学科、跨领域的不断探讨,共同助力技术创新上、中、下游的对接与耦合。

往期回顾

医路领航第三期数字疗法重新定义精神健康治疗

医路领航第二期人工智能赋能药物研发

医路领航第一期AI如何助力数字化战疫 

哈佛中国健康协会是哈佛大学首个专注于中国医疗系统系统和健康产业的学生组织,致力于通过对话顶尖世界学者及行业领袖、中国产业参访行和专题研讨会等活动,帮助哈佛学生学者打破学术和产业界的信息壁垒、深入探讨中国医疗健康发展趋势,凝聚专业化的人才网络,启迪未来医疗健康领域的引领者。


有興趣在美國長期發展的朋友看過來囉!

波士頓台灣人生物科技協會 (BTBA) 與哈佛台灣學生會 (HTSA) 將合作舉辦「綠卡&H1B申請線上講座與經驗分享」,邀請綠楓法律集團創所律師陳啟耕律師 (Danny Chen) 主講綠卡及H1B申請的過程,並邀請三位不同身份轉換取得綠卡的學長姊分享自身經驗。本講座將包含以下主題:

- 各種身份 (F, J, OPT)如何銜接轉換綠卡或H1B?
- 何種條件、時機可以開始申請綠卡?要累積什麼經驗、資歷對申請綠卡有幫助?
- EB1、EB2申請難度及條件?
- 學長姊過來人經驗分享,若時光倒流他們會/不會做的事是什麼?
- 近期移民政策對申請綠卡、H1B的影響

歡迎同學們和BTBA的各位,請先填寫與會報名表,也讓我們知道你有什麼問題,我們會先行告知律師和學長姐準備回答你的問題喔!
https://forms.gle/yDByicWFSp73MdUk6

[活動分享] BTBA monthly Seminar!
=========================================
BTBA Monthly seminar is back! We are happy to have two outstanding scientists from the Harvard community to present their recent work.
*Kai-Ting Shade (Instructor, Massachusetts General Hospital)
"Sialylation of immunoglobulin E is a determinant of allergic pathogenicity"
*Annie Cheng (Postdoc, Brigham and Women's Hospital)
"Nanoparticles: A multifunctional vehicle for theranostics"
Moderator: Jerry Lin (Postdoc, Massachusetts General Hospital)
Meeting link coming soon!
SAPANE獎學金9/18報名截止






最近開始有點秋天的氣息,就表示新的年度又要來了!!感謝過去一
路以來大家的支持和鼓勵,就是下週日9/13,
BTBA-Boston Taiwanese Biotechnology Association
要來舉辦2020-2021 Welcoming party!!
走過路過不要錯過~ 派對上我們要一起來討論接下來新活動內容,另外也想聽取大家的意見跟未來活動喜好。相較於過往的學業界活動,新的一年我們還有新面向的互動方式喔~ 希望在這個疫情期間,BTBA的大家可以透過迎新趴認識一下新來到波士頓的朋友,還有一路陪伴的老朋友們!
滑鼠往下按連結就可以報名參加這次的迎新派對了! 希望下週日可以線上見囉! 如果有任何問題歡迎聯絡今年負責人
22021 BTBA VIy
We are excited to invite everyone to come and join 2020-2021 Boston Taiwanese Biotech Association (BTBA) Virtual Welcome Party on September 13, 2020!

Hope everyone is well, healthy, and safe during the pandemic. As the new school year arrived, BTBA welcomes everyone who calls Beantown a new home to join our virtual welcome party on September 13, 2020! No matter you are an academic professional, a biotech professional, a postdoctoral researcher or a student, we sincerely invite you to come and connect with us. At BTBA, you will find a group of passionate scientists and enthusiasts to network and discuss career opportunities & possibilities, healthcare related topics, life science research, pharmaceuticals, drug discovery start-ups as well as the innovation and technology that powers it all.
We thrive because of you!
We are thrilled to get to know you, so come and join us!

各位親愛的朋友,大家好!希望大家在COVID期間都健康平安! 新的學年又要開始囉!波士頓台灣人生物科技協會 (BTBA) 今年的第一場活動將在 9月13日 登場~! 歡迎新朋友&老朋友一起來互相認識,不管是來念書,來工作,來當Postdoc,都不要錯過BTBA的活動。不是生物領域,也沒有問題!來聽聽看新的一年可以有甚麼精彩可期的活動!

時間 / Time:
2020-09-13 (Sun) 1 pm - 3 pm

地點 / Place:
Microsoft Team Meeting
Meeting link will be sent separately, please make sure leave your e-mail below!

聯絡人 / Contact:
Yvonne Meng 孟憲薇; hsienweimeng@gmail.com
Erica Cai 蔡佩珊; ericapscai@gmail.com

Please complete this form to RSVP (Registration is free!).

Follow & Like us on Facebook: https://www.facebook.com/btbatw/

會議流程 / Event:
1:00 am – 1:30 pm Meet and Greet
1:30 pm – 2:00 pm BTBA Introduction
2:00 pm – 3:00 pm Networking


美中藥協年度科學盛會【2020 SAPA科學論壇】將於8月15日(星期六)以網絡會議形式舉行。

今年主題是“生物醫學創新轉型的驅動力”,將重點關註生物醫學創新在🩺診斷與精準醫學,🧬細胞與基因療法,以及藥物研發的新技術等領域的最新趨勢與突破。世界知名的科學家,包括哈佛大學的George Church教授和斯坦福大學的Richard N. Zare教授,以及諸多製藥行業領導者、科學家和企業家,將分享他們對生物醫學創新的思考與見解。 🔛論壇還設有互動交流小組會議,提供了同主講人和資深業內人士在線面對面交流的機會。
SAPA會員福利免費註冊 ,學生註冊享優惠!
⏰時間:2020年8月15日 週六 9:00 AM-5:00 PM EDT
🔗註冊鏈接:https://sapaweb.org/event/2020-scientific-symposium/

2020 BTBA Virtual Symposium in two weeks!!!
This year, we are honored to have Dr. Taiyin Yang, the Executive Vice President of Gilead Sciences, who supervised the development of Remdesivir, to deliver the keynote address.
Please also check out the rest of meeting agenda!
*Flyer designed: Amy Kao

7月11日 OCEAN-BIO SEMINAR:中美投资并购中的国家安全审查和出口管制问题

 OCEAN BIO 海华会生物分会 2 days ago
2020年02月13日,美国财政部于今年年初颁布的全面实施《2018年外国投资风险审查现代化法案》(Foreign Investment Risk Review Modernization Act of 2018)(“FIRRMA”)的两项最终实施条例(“实施条例”)正式生效实施。


FIRRMA及其实施条例正式施行后,有可能给未来的中美投资及并购带来“寒蝉效应”。中美投资并购活动将面临更为复杂的监管环境,必须及时从国家安全审查角度进行有效的评估,并据此提前进行合适的筹划安排。





00100


2020年07月11日,海外华人企业家联合会生物分会(OCEAN-BIO)将邀请著名国际律师事务所Dorsey & Whitney(德汇律师事务所)合伙人、德汇全美及中国联合业务主席——潘惜唇律师,为大家做“中美投资并购中的国家安全审查和出口管制问题”的主题演




直播时间
美东时间 2020年7月11日,周六,晚八点
July 11, 2020, Saturday, 8PM, US Eastern Time
Zoom Link: https://us02web.zoom.us/j/8151859178
Zoom ID: 815 185 9178
Mobile:  +13126266799, 8151859178# US (Chicago)
             +19292056099, 8151859178# US (New York)

----------------------------------------------------------
本次网络直播会议
对全球华人企业家免费开放

SAPA 健康投资论坛暨路演六月线上举行 项目资本双向征集

 SAPA-HQ 美中药协SAPA 3 days ago



2020 SAPA Roadshow
新冠肺炎疫情给全球社会经济带来深刻影响,整个创业生态和风险投资领域面临着极大的冲击。然而“危”中有“机”,医药健康行业逆行而上获得高度关注,疫情同时也激发产业变革,催生新的发展机遇。

2018年以来在大纽约地区名声鹊起, 广受投资人和企业家们喜爱的美中药协(SAPA)旗舰活动 – 2020 SAPA健康产业投资峰会暨项目路演,将因时而变,重新设计为线上和线下两个部分:第一部分为线上部分,包括投资论坛有关投资和创业的主题演讲和讨论,一系列的线上路演,1对1会议。

首轮路演将于2020年6月20日举行。第二部分线下会议将在10月初的SAPA 2020年会上举行。
在这里,您将通过SAPA创投平台:
•  了解最新生物医药的投资和研发最新动态
•  与顶尖的投资人交流互动
•  与天使轮到Pre-IPO的各类投资人和各大药厂的BD高层交流互动,了解投资全周期细节
•  企业家和投资人1对1会面,充分展示/了解项目和交流融资兴趣
•  除了获得投资,还可能有对外授权技术和产品的机会
•  获得SAPA药界资深专家和投资界人士的专业评审和建议
•  与同行交流分享经验心得
•  广结善缘,获得更多潜在的人才与合作伙伴资源
•  全线上活动,无地域限制,低成本参与,会后可观看活动录像
征集路演1对1项目

项目报名要求
生命科学行业,包括但不限于:制药生物技术公司医疗器材诊断与数字化健康公司。
每一份申请都会由SAPA投资论坛组委会认真严格审阅,最为优秀的部分项目会邀请在投资论坛进行线上路演,或与投资人进行线上1对1会面。

请填写下方的Google form或者QQ survey报名:
• Google form:  
https://forms.gle/ks8DLZLj5X7BnXUF9
• QQ survey, (如无法使用Google form):
 https://wj.qq.com/s2/5912374/a9d1
征集投资者

我们将邀请知名生命科学领域投资机构投资人担当路演评委。同时也欢迎对活动感兴趣的投资人以及公司BD联系我们,商务拓展负责人及其他相关人员联系我们参加1:1会议。
请填写下方的Google form或者QQ survey
•   Google form:
  https://forms.gle/hU2xYhNQ2N32m5A36
•   QQ survey, (如无法使用Google form):
  https://wj.qq.com/s2/6153302/f8f3
 
首轮线上创投路演报名截止时间
2020年5月29日,星期五,11:59 pm (EDT)
若有疑问或了解更多详情请联系
roadshow@sapaweb.org
欢迎合作伙伴与赞助商

同时,SAPA也邀请您成为我们的合作伙伴与赞助商!具体方式详见下方宣传手册,有意向者请联系:fundraising@sapaweb.org

本次活动稍后将开放观众注册,敬请关注SAPA微信公众号和SAPA LinkedIn主页!
8BTBA Annual Symposium]🔥🔥🔥
8屆的台灣人生物科技協會(BTBA)年會將在711日於隆重登場!學生會是活動的Co-Host~
因應疫情,今年將改為半天的線上活動,雖然時間縮短,但一樣內容精彩可期,邀請了吉利德藥廠的講者來擔任Keynote speaker。更多資訊將在6月陸續公布,期待跟大家線上見!
BTBA是由在波士頓從事生物、醫學、科技相關的台灣學者、博士、學生組成的社團,希望能互相給予彼此在專業、研究上發展的支持
👉更多資訊,請發落粉專:https://www.facebook.com/btbatw/
👉BTBA Monthly seminarhttps://www.facebook.com/events/842317972853712/


















注册链接 https://zoom.com.cn/webinar/register/2915864885850/WN_AlNghXDqQlO36-IP508RPg

2020 World Medical Innovation Forum | Virtual, Interactive, State of the Art | Monday, May 11

Our Mass General Brigham Harvard faculty including front line clinicians, CEOs and top journalists will examine the coronavirus response, the future of medicine, and AI. Reporters from the New York Times, TIME and CNBC will moderate. Added highlights are digital adoption, new infectious disease technology, investment prospects and national security leadership perceptions on health care challenges and opportunities.
Register today for this year’s leading virtual event. There is no charge.


Join Us and Get Answers from a doctor / epidemiologist- What You Need to Know About COVID-19
JOIN at https://harvard.zoom.us/j/861442364
This is a rapidly evolving situation. Many information is confusing and not relevant to yourself. I thought it would be best to have a communication with a physician who experienced SARS outbreak, and then now COVID outbreak. Dr. Lin is an infectious expert, received his medical training from National Taiwan University and doctorate degree from Harvard.
Speaker: , Dr. Hsien-ho Lin, MD, ScD.林先和
About
http://www.daai.tv/news/life/241795
Agenda:
8pm -8:15pm sharing (Hsien-ho)
8:15-8:30pm Q&A (general public)
#重量級講者 #Baxter台灣總經理 #數位醫療趨勢 #腹膜透析
隨著破壞性科技如AI、物聯網的應用在醫療照護領域逐一落地,醫療數位化與智慧化已成為未來醫療的趨勢。比翼加速器很榮幸能邀請到國際前十大醫材廠Baxter 臺灣&香港區總經理Gary Wang 來分享 “ Embrace the Digital Healthcare Future”。
Baxter (NYSE:BAX) 為全球前十大醫材廠,主要專注於腎臟與腹膜透析領域。總經理 Gary 將分享當前數位醫療的趨勢,並進一步介紹Baxter 如何在數位醫療領域創新及結合數據打造更好的醫療服務。
Gary Wang 在醫療領域有長達25年的豐富經驗,除了Baxter 外曾任職於GSK、楊森藥廠、SANOFI。同時Gary也是香港科研製藥協會 (The Hong Kong Association of the Pharmaceutical Industry) 的成員。更多資訊詳見Gary的LinkedIn: https://www.linkedin.com/in/gary-wong-a1768534/
附註:本次活動將以英文進行


2019-2020 BTBA Seminar series

  • Sunday, December 8, 2019 at 2 PM – 3:30 PM EST
    Tomorrow
  • MIT Building E25: Room 119/121

[11/17/2019]
Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves
Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

[12/8/2019]
Jim Chou 周駿:
Plotting against cancer: which killers to hire?
Zhongyou Li 李忠佑:
The immune regulatory effect of a 5' tRNA half in outer membrane vesicles induced by tobramycin

[01/26/2020]
Vicky Chen-ching Yuan 袁禎璟
Zoe Liu 劉紀秀

[02/23/2020]
Po-Cheng Lin 林柏成
Szu-Ta Chen 陳思達

[03/22/2020]
Fan-Yun Lan 藍凡耘
Ying-Chih Lo 羅盈智

[4/19/2020]
I-Cheng Ho 何宜虔
Chi-Hua Yu 游濟華

[5/17/2020]
Pin Kuang Lai 賴品光
Jason Lu 盧彥君

[6/14/2020]
Chia-En Lien 連加恩
Chi-An (Annie) Cheng 程吉安

The 11th CABA MDDI SYMPOSIUM

















11th MDDI
Precision Medicine


The 11th CABA Medical Device and Diagnostics Innovation Symposium (MDDI), co-sponsored by NECINA and HMS CSSA, is scheduled for Saturday, December 14th, 2019 at the Conference Center at Waltham Woods, 860 Winter St, Waltham, MA 02451.  

The annual MDDI Symposium is a major CABA event that attracts prominent entrepreneurs, investors, biotech and pharmaceutical executives, academic and industry scientists, as well as professionals in the legal, financial, and healthcare industries, both locally and internationally. Past symposiums were extremely well attended. More than 200 professional attendees will be expected.

The theme of this symposium is “Precision Medicine”. Tailoring medical treatment to the individual characteristics of each patient not only has the potential for better therapeutic outcomes, but also provides crucial information for healthcare decision-making. A holistic assessment of patients' data, including genomic, epigenetic, and clinical information, will offer great insights on and better approaches to effective treatment. Topics of the symposium will include classification of human cells into subpopulations for CAR-T therapy, application of AI in kidney pathologic diagnosis, and novel biomarkers on clinical mass spectrometry for better maternity diseases management. 

Speakers
  • John Hallinan, MassBio Chief Business Officer
  • Wilson Zhang, CEO/ Milu Labs
  • Regina Au, Principal, New Product Planning/Strategic Planning, BioMarketing Insight
  • Mingru Wu, Cancer Immunology & Virology; Dana-Farber Cancer Institute, Member of Faculty Department of Immunology; Harvard Medical School
  • Shen Luan, Senior Director, Thermofisher Science
  • Allena J. Ji, Director of Clinical Mass Spectrometry Laboratory, Sanofi

Symposium  December 4th, 2019, Boston, USA  “Gene Regulation in Differentiation and Cancer” Agenda 
        8:45-9:15 Registration and Continental breakfast 
        9:15-9:30     Opening Remarks         Alan Rosmarin, M.D. 
        9.30-11:15              Session I:     Chair: Dr. Alan Rosmarin   9.30-10:00   Keynote Speaker Jonathan Licht M.D.  Director- The University of Florida Health Cancer Center,  The Marshall E. Rinker, Sr. Foundation and David B. and Leighan R. Rinker Chair             Disorders of histones and histone methylation in cancer  
       10:00 to 10:15         Ulrich Steidl, M.D. Ph.D.                Lineage Commitment and Differentiation – 15 years later 
  10:15-1:30   Shannon Elf, Ph.D.             Identifying novel molecular dependencies in CALR-mutated myeloproliferative neoplasms  
             10:30-10:45               Huimin Chen, M.D. Ph.D.                        3D Bioprinting Application in Cartilage Repair 
10:45-11:00               Annalisa DiRuscio, M.D. Ph.D.                RNAs: the real writers of the epigenetic code 
11:00-11:15               Sophia Adamia, Ph.D.                             AML epigenetics for the 21st century: novel biomarkers and drug targets 
  11:15-12:30   Session II                Chair: Dr. Ulrich Steidl 
11:15-11:30               Dong-Er Zhang, Ph.D.                    Dynamics of RASSF2 in leukemogenesis 
11:30-11:45               Justin Wheat, Ph.D.                Single Molecule Analysis of Spi1 Transcription Dynamics During Differentiation 
11:45-12:00               Meritxell Alberich-Jorda, Ph.D.                Chronic inflammation, stem cells and leukemia 
12:00-12:15               Britta Will, Ph.D.                Novel safeguards of hematopoietic stem cell identity 
12:15-12:30               Barbara Wegiel, Ph.D. Scavenging of free heme by hemopexin is a key check-point in cancer growth and     metastases 
12:30-1:30               Lunch break 
1:30-3:30               Session III               Chair: Dr. Dong-Er Zhang 

 1:30-2:00              Keynote Speaker              David Livingston, M.D.,  Deputy Director, Dana-Farber/Harvard Cancer Center  Chief, Charles A. Dana Division of Human Cancer Genetics Emil Frei Professor of Genetics and Medicine,   Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts              En route in a normal mammary epithelial cell to BRCA1 breast cancer 
2:00-2:15               Dan Costa, M.D., Ph.D. Dan Tenen and lung cancer: an accidental encounter that helped revolutionize precision    oncology 
2:15-2:30               Gang Huang, Ph.D. Pseudohypoxia - An Underlying Mechanism and therapeutic Target of Myelodysplastic Syndromes 
       2:30-2:45               Hideyo Hirai, MD. Ph.D.                   C/EBPbeta isoforms regulate hematopoietic stem cells under stress condition 
 2:45-3:00               Philipp Staber, MD. Ph.D.                   Identifying functional switches in hematologic malignancies 
3:00-3:15               Rob Welner, Ph.D.                   Targeting Leukemia through the Marrow Microenvironment 
3:15-3:30               Anne Satterthwaite, Ph.D.                   Signals controlling plasma cell accumulation and autoantibody production in lupus 
3:30-3:45               Coffee Break          
3:45-5:30               Session IV               Chair: Dr. Dan Costa 
       3:45-4:00               Alan Rosmarin, MD.                                         A tribute to Dan Tenen 
4:00-4:15               Elena Levantini, Ph.D.  Identification of a targetable KRAS-mutant epithelial population in NSCLC 
      4:15-4:30               Li Chai, M.D.                  Targeting SALL4 in Cancer 
4:30-4:45               Omid Harandi, Ph.D. MRNA-based Engineering of Red Cell Therapeutics (RCTs) to Generate Potent, Allogeneic Cellular Therapies 
4:45-5:00               Bon Trinh, Ph.D.                   RNA Regulation of Promoter-Enhancer Communication  
5:00-5:15               Balazs Halmos, MD. Ph.D.                   Precision lung cancer medicine- a "personal" journey 
5:15-5:45              Closing ceremony              Daniel G. Tenen, M.D.  
5:45-6:00              Group Picture 
6:00-8:30              Dinner party (Invited only) 

Honoring Daniel G. Tenen, M.D.  
For his many contributions to the scientific community 
 Date: Wednesday December 4th, 2019    
 Time: 8:45am – 6:00pm 
 Location: DFCI Jimmy Fund Auditorium Binney Street, Boston, MA, 02115 
Symposium Committee Co-Chairs   Alan G. Rosmarin, M.D. Deputy Editor of Hematology at UpToDate Chief Mission Officer, the Samuel Waxman Cancer Research Foundation.   Dong-Er Zhang, Ph.D. Professor of Pathology and Biological Sciences University of California San Diego Moores UCSD Cancer Center La Jolla, CA   Ulrich Steidl, M.D., Ph.D. Professor of Cell Biology and Medicine, Albert Einstein College of Medicine - Montefiore Medical Center New York, NY   Daniel Costa, M.D., Ph.D. Associate Professor of Medicine, Harvard Medical School Co-director Lung cancer research program within Cancer Research Institute at BIDMC Co-leader of the lung cancer program at Dana-Farber/Harvard Cancer Center 
Symposium Organizing Committee Contacts:  gang.huang@cchmc.org lchai@bwh.harvard.edu pu.zhang@Novartis.com 
Gene 

Special Talk//台灣大學農學院 盧虎生 院長:台灣農業的現況: 生物經濟及智慧農業
Friday, November 15, 2019 at 5:30 PM – 7:30 PM EST
TMEC 250 mini amphitheater, 260 Longwood Ave, Boston, MA 02115

*講者: 臺灣大學生物資源暨農農學院長盧虎生教授
*講題: 台灣農業的現況: 生物經濟及智慧農業

*時間: 11/15/19 (Fri) 5:30 pm

*地點: Harvard Medical School TMEC 250 Mini amphitheater

(260 Longwood Ave, Boston, MA 02115)
http://www.bioagri.ntu.edu.tw/cbaintro03.php
*提供簡單茶水點心

(感謝TECO贊助協辦)

哈佛医学院华人专家学者联合会 
Chinese Scientists and Scholars Association at Harvard Medical School
HMS-CSSA
微信公众号: hmscssa
HMS-CSSA助手微信号:hmscssa2007
(添加好友后可由助手号邀请加入 HMS-CSSA 学术群、HMS-CSSA 生活群)

2019美中生物医药协会投资创业论坛

 Jo Lee CABA
















2019美中生物医药协会投资创业论坛
2019 Chinese-American BioMedical Association (CABA) Investment and Entrepreneurship (IE) Symposium
2019年9月28日(周六)美东时间早上8点 
Boston Marriott Newton 
2345 Commonwealth Avenue 
Newton, Massachusetts 02466 USA
活动介绍
2019美中生物医药协会投资创业论坛又将如期登陆波城,现论坛诚邀各位怀揣热情的投资人及创业者共同参与。自2008年起,IE论坛已经连续多年于波城举办并且取得圆满成功。我们持续与生物制药创业公司和投资者携手合作,发掘并推动制药领域的投资创业。此次IE论坛,我们再次邀请到多位来自工业界和学术界的专家,以及资深的投资人和律师,就生物制药领域的一系列前沿话题进行交流探讨,并提供针对行业现状及未来趋势的重要见解。
Nandita Shangari, Ph.D.       Principle, Novartis Venture Fund
Brian Gallagher, Ph.D.   Partner, Abingworth
Hong Cheng, Ph.D.     Head of Research Strategy, Sanofi
Lixin Shen, Ph.D.     Founder and Chief Executive Officer, Guangzhou Alagen PharmTech
Yihan Wang, Ph.D. Founder and Chief Executive Officer, Shenzhen TargetRx, Inc.
Yongzhong Wang, Ph.D.      Chief Executive Officer, CMAB Biopharma
Linda Ji, J.D.     Partner, McDermott Will & Emery
Hugh Davis, Ph.D. Chief Business Officer, Frontage Laboratories, Inc
Jens Stephan, Ph.D.      Professor, East Michigan University
Dapeng Sun, Ph.D. Chief Technology Officer, ABclonal Technology
John Giszczak Vice President, Business Development MORE Health
Shaoyu Chang, M.D.    Vice President, FC Capital
Pengpeng Li, Ph.D.  Analyst, 5AM Ventures
Joe Zhou, MBA  Fouding Partner, BAC Investment
Hongkai He      Venture Partner, Skylight Investment
Jianying Shi, Ph.D.  Vice President, HD Biopharmaceuticals
Michael Zhao    Founder, QTang Ventures
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association
The 2019 BTBA symposium will be held on August 3-4th at Harvard University Northwest Science Building, Cambridge, MA. This event will feature more than 20 speakers, including experts who lead clinical development activities in human diseases, and professionals in the field of gene regulation and molecular immunology. We have crafted an agenda that includes inspiring presentations and interactive forums focused on the novel technologies in synthetic biology, penetrating insights into biotech environments around the US and practical experiences about how to survive in academia/industry. No matter you are biotech entrepreneurs, professionals or students, you can find what you need to advance your future career in here. Please join our annual symposium by registering here>>>

👉👉👉👉👉Ticket: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

👍👍For more information, please visit our website: http://btbatw.org/2019/website


一年一度的BTBA symposium開放售票囉!!
來自各個領域的專家 數十載企業實戰經驗 透徹犀利的職場分析 全部無私分享給你
還在等甚麼,還不趕快來報名!!!!!!!
時間: 2019 Aug 3-4th
地點: Harvard University Northwest Science Building
🎈🎈🎈報名連結: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

2019 SAPA-NE 21st Annual Conference
Deliver Optimal Medicines to All Patients
(Boston Cambridge Marriott, June 8th, 2019)

秉承20年发展壮大的辉煌,胸怀治愈人类疾患的梦想,新英格兰美中医药开发协会SAPA-NE将于2019年06月08日在Boston Marriott Cambridge 宾馆 (50 Broadway, Cambridge, MA) 隆重举行第21届年会。届时,学术精英、企业领袖、投资英才、药界同仁等将云集全球医药创新的圣地—波士顿剑桥,围绕Developing and Delivering the Advanced Medicines to All Patients 的会议主题展开学术交流、共同探讨人类医药事业发展之未来。欢迎光临,敬请注册。
更多详情:https://www.sapa-neweb.org/ac2019 
注册链接(早鸟截至日期:5/17/2019):https://www.sapa-neweb.org/ac2019event
Upcoming Event: 2019-06-08 SAPA-NE 21st Annual Conference: Deliver Optimal Medicines to All Patients
Selected keynote speakers:
* Edward Hu, Co-CEO, WUXI AppTec
* Sridaran Natesan, PhD, Vice President, Sanofi
* X. Shirley Liu, PhD, Professor at Dana–Farber Cancer Institute and Harvard T.H. Chan School of Public Health
* Brad Loncar, CEO, Loncar Investments
* Shi Wenzhao, President of Digital China Health Technologies Corporation Limited
* Shaun R. Coughlin, MD, PhD, VP, Global Head of Cardiovascular and Metabolism at Novartis
SAPA-NE 2019 年会将集中探讨医药行业前沿,热门人工智能,大数据分析,先进肿瘤免疫疗法,多重治疗模式,等等话题。会议还将组织CEO论坛,与大家面对面分享经验。精彩不容错过,欢迎光临,敬请注册:https://www.sapa-neweb.org/ac2019 (早鸟截至日期:5/17/2019:https://www.sapa-neweb.org/ac2019event )
Speaker介绍:Gregory Verdine博士
FogPharma由生物技术领域知名连续创业家、哈佛大学终身教授Gregory Verdine博士创立。这家新锐公司致力于突破现有的常规手段,找到全新的新药分子。其核心技术是Verdine教授在哈佛大学研发的新型技术- 可穿透细胞的迷你蛋白(CPMP)。它有望靶向“不可成药”的靶点,为新药发现与研发带来变革。
除了FogPharma之外,Greg Verdine博士还创办并领导了LifeMine Therapeutics,该公司创建了首个基于真菌基因组的药物开发平台,可以高效快速开发新药。LifeMine Therapeutics和FogPharma总部都设在马萨诸塞州剑桥,并于2016年成立。Verdine博士因其在生涯中担任生命科学家,企业家,投资人和首席执行官的成功角色而得到高度评价。他是哈佛大学和哈佛医学院的Erving教授,先后创建了多家纳斯达克上市的生物技术公司,包括Wave LifeSciences,Enanta,Eleven Bio,Variagenics,Tokai,Aileron和一家私有公司Gloucester制药公司,由Celgene于2010年收购。





Sino-American Pharmaceutical Professionals Association
New England (SAPA-NE)
High School Excellence Scholarship Program

Eligibility
The applicant must meet the following criteria:
  1. The applicant must be a United States citizen or legal resident alien residing in the New England area (MA, NH, RI, VT, CT, ME).
  2. The applicant must be a graduating high school senior with a GPA of 3.3 (out of 4.0) or greater and an SAT score above 1450 (out of 1600) or equivalent.
  3. The applicant must be enrolling for the first time in a full-time undergraduate course of study at an accredited 4-year college or university in the upcoming academic year. The applicant should pursue or intend to pursue a major related to life sciences.
  4. Members of SAPA-NE Board of Directors, the SAPA-NE Advisory Committee, or the SAPA-NE Scholarship Selection Committee cannot participate on the selection process. Any member of the SAPA-NE Executive Committee must disclose should his or her relative become an applicant. Failure to disclose a position of conflict of interest will not only disqualify the candidate, but also lead to disciplinary action towards the executive member.

Application procedures
Application materials
The applicant must submit:
  1. A brief resume illustrating major accomplishments during the applicant’s K-12 education
  2. An essay (~600 words) to illustrate what the applicant will be pursuing at college and what inspired him or her to make such a decision
  3. A recommendation letter from the school counselor and two letters of recommendation from teachers who can attest and comment on the applicant's achievements and development potentials
  4. A copy of high school transcript and a copy of standard test results.
  5. A copy of acceptance letter from the college the applicant intends to enroll
  6. An application fee ($30) needs to be submitted along with the application. Please make any checks payable to SAPA-NE. The application fee can be waived if the applicant’s parent or legal guardian is a member of SAPA.

Online application form is available: http://www.sapa-neweb.org/scholarship-application/. You may fill in the online application form, print the application, and send the application along with recommendation letters, a copy of acceptance letter from the college, and application fee to the following address.
Application Deadline
May 17, 2019 (Postmarked)
Application Mail Address:
Please enclose ALL the materials, including sealed recommendation letters, in ONE package and send to SAPA-NE:
SAPA-NE High School Excellence Scholarship
12 Arbor Lane, Winchester MA 01890
Email Addresses:
Please notify Drs. Huo Li and Guiqing Liang after you send out the application
Huo Li: huoli2@gmail.com;  Guiqing Liang: lianggq1@gmail.com
Selection Procedures
An independent Scholarship Selection Committee appointed by the SAPA-NE Executive Committee will evaluate all valid applications and nominate several strongest candidates. SAPA-NE Executive Committee will make the final selection of up to three award recipients.
Applicants will be evaluated on:
  1. Academic performance, leadership quality, and community/school service.
  2. Demonstrated potential and commitment to a career aspiration that has a broad impact in the society.
Award Acceptance
Recipients of 2019 SAPA-NE High School Excellence Scholarship will be notified by Scholarship Selection Committee by email and will also be posted at SAPA-NE homepage http://www.sapa-neweb.org/scholarship.

Upon contact by Scholarship Selection Committee, a SAPA-NE Scholar must submit an acknowledgment letter stating the acceptance of the scholarship award. The recipients (required) and their parents/legal guardians (optional) will attend the 2019 SAPA-NE High School Excellence Scholarship Award Ceremony at 21st SAPA-NE Annual Conference on June 8, 2019 at Boston Marriott Cambridge, Cambridge MA. A short speech (5 minutes) made by each award recipient will be expected at the ceremony. Each recipient will be awarded up to $1000 one-time scholarship.
2019 Boston BioForum (CABA) Driving Transformation in Life Sciences Industry
2019波士顿生物医药论坛| CABA
Date and time: Saturday, May 4, 2019 @ 8AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451

The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields to talk about hot topics in the Life Science industry.
  • Future of Immuno-Oncology
  • Outlook of Cell & Gene Therapy
  • AI & Big Data in Health
  • Evolving Landscape for Life Science Investment
  • Next Big Thing in Biotech & Pharma
Speakers

  • Will Brownsberger
    MA State Senator

  • Jos Melenhorst
    Director, CAR-T Product Development
    University of Pennsylvania

  • Jonathan Terrett
    Head of Immuno-Oncology
    CRISPR Therapeutics

  • Sadik Kassim
    Executive Director
    Kite Pharma

  • Nenard Grmusa
    SVP, Head of External Innovation
    Takeda

  • Lei Xiao
    CEO
    Innovative Cellular Therapeutics

  • Derrick Li
    Head of Strategy and Investor Relations
    Cellular Biomedicine Group

  • Nick Valiante
    Founder and CEO
    Glyde Bio

  • F. Stephen Hodi
    Directot, Center for IO
    Dana Farber Cancer Institute, Harvard Medical School

  • William Cao
    CEO
    GraCell Bio

  • Weichang Zhou
    Chief Technology Officer
    Wuxi Biologics

  • Scott Brown
    Director
    Computational Chemistry
    Sunovian

  • Catherine Sabatos-Peyton
    Direcctor
    Novartis Institutes for BioMedical Research

2019年哈佛华人生物医学年会

 HMS-CSSA HMSCSSA 3/23

欢迎大家参加哈佛大学2019年华人生物医学年会!本次学术年会将于4月28日(周日)在波士顿儿童医院召开 。参会报名请见文末注册链接(.edu 邮箱注册免费)。

哈佛华人生物医学年会学术论坛自2009年举办以来,每次都吸引了数百名来自中国和美国学者参加,已成为中美生命科学和医学领域重要的学术会议之一。今年的学术论坛恰逢此学术盛会十周年,将覆盖从基础研究到肿瘤治疗,从技术创新到临床应用的最新进展,涵盖肿瘤免疫学、表观遗传学、神经学、转化医学等多个热门和前沿课题。

邀请的十位演讲嘉宾包括:
(图片可轻按放大)

姓名
单位、职务
研究方向
施扬
哈佛医学院,波士顿儿童医院
可控的表观遗传机制和转录调节因子
Harvey Lodish
麻省理工学院生物工程系、Whitehead研究所创始成员;美国科学院院士,《分子细胞》作者
红血细胞,脂肪细胞功能及生物疗法应用;长链非编码RNA功能
何志刚
哈佛医学院、波士顿儿童医院
中枢神经系统损伤和其他神经系统功能的恢复
Ed Boyden
麻省理工学院、神经技术学
复杂生物(大脑)系统和功能的修复
任兵
加州大学圣地亚哥分校基因组医学研究所
人类胚胎干细胞分化和哺乳动物发育的基因组、表观基因组的分析
袁国丞
哈佛陈曾熙公共卫生学院、丹娜-法伯癌症研究所
计算生物学与生物信息学基因组分析以理解基因调控机制
蔡理慧
麻省理工学院Picower学习与记忆研究所所长
神经修复与阿尔兹海默症
冯国平
麻省理工学院大脑与认知科学系
神经突触和环路功能及精神疾病发生机理
刘勇军
赛诺飞研发高级副总裁兼全球研究负责人
肿瘤免疫转化医学
陈建柱
麻省理工学院生物学系
免疫记忆,抗肿瘤T细胞反应;人源小鼠模型的建立和应用

除了演讲之外,我们还会和CAHON(www.cahon.org; 美国华裔血液和肿瘤专家学会)一起组织一个 Immuno-oncology Panel Discussion和大家就最新的热点领域进行交流

(图片可轻按放大)

年会上我们还会颁发2019年度哈佛杰出华人生命科学研究奖(Harvard Chinese Life Science Annual Distinguished Research Award),欢迎大家自行报名或提名朋友同事,具体信息请参见下一篇公众号文章内容。






























The Harvard Chinese Life Science Annual Symposium (HCLS) is the signature event organized by HMS-CSSA. The symposium covers basic life science research, translational medicine, and biopharmaceutical industries. It draws hundreds of attendees working in life science-related areas in the U.S. and China.


Time:
Sunday, April 28th, 8:30 AM - 5:00 PM

Location: 
Folkman Auditorium, Ender's Building
Boston Children's Hospital
320 Longwood Ave, Boston, MA 02115










































年度盛会,精彩内容,诚邀您的参与。


长按识别以下二维码进行注册(或点击文末“阅读原文/Read more”)
Refreshment and lunch will be provided with RSVP! 


















































































HMS-CSSA is a non-profit organization operated by volunteers who are full-time postdocs, students or visiting scholars at Harvard Medical School and its affiliated hospitals. We aim to create a platform for networking, cooperation, and career development among our members, hence serving as a bridge for intercultural communication between China and US.
This year’s event is the 10th  annual meeting organized by HMS-CSSA, and HCLS Annual Symposium has become more influential and more recognized and appreciated by the HMS Chinese community during the years. Every year, more than 500 people register and attend the one-day-long symposium in person or watch the live broadcast online. Last year, Dr. George Daley, Dean of Harvard Medical School, gave the opening remarks. Last few years’ speakers include Lieping Chen, Gordon Freeman, Xiaoliang Sunney Xie, Chuan He, Shirley Liu, Matthew Meyerson, Yang Shi, Hao Wu, Kai Wucherpfennig,Tian Xu, Junying Yuan, Feng Zhang, etc.  
The 2019 symposium will be equally exciting that Dr. Harvey Lodish, Dr. Yang Shi and Dr. Yongjun Liu etc. have accepted our invitation. We sincerely invite you join us! Your presence will make this year's program more exciting with more impact! 


































文案:唐爽 梁丹 祁亚楠 萧安 岳宏
编辑排版:萧安 李江

【YSA x Z-Park】构建精准医疗未来版图(Frontiers in Precision Medicine)

YSA 青年学者联盟YSA 2 days ago
































点击青年学者联盟YSA关注公众号

本期的Frontiers系列的话题是精准医疗(Precision Medicine),YSA和Z-Park有幸邀请到精准医疗领域优秀的企业家来给大家分享构建精准医疗未来版图。

With dramatic decreases in cost andturn-around time, next-generation sequencing (NGS) has become a powerful tool for basic research and various clinical applications. From the study of disease mechanisms to the search for predictive biomarkers to the design of personalized cancer vaccines, NGS is increasingly employed in applications of precision medicine.

Speakers:

Jeff Cheng, Ph.D.
Chief Scientific Officer at Novogene

Talk title: Leading Edge Next-Generation Sequencing and Bioinformatics Services

Jeff Cheng, PhD, is currently the Chief Scientific Officer and Global Head of Biopharmaceutical Services at Novogene Corporation, a global next-generation sequencing and bioinformatics provider.

Prior to joining Novogene, Jeff was the Biomarker Science Leader and China Site Head in the Department of Oncology Biomarker Development at Genentech and Roche Product Development in Asia Pacific. Before that, he was the Head of Scientific Liaison for Biomarker Research at Roche Pharmaceuticals in Shanghai and a Principal Investigator of In Vivo Oncology at BeiGene among other positions.

Jeff obtained his Bachelor’s degree in Chemical Engineering from Tsinghua University in Beijing, China. He then went to Rice University for his PhD in Chemical and Biomolecular Engineering which was followed by a post-doctoral research fellowship at Massachusetts General Hospital and Harvard Medical School. His research there was focused on vascular biology and tumor micro-environment.

Mark Driscoll, Ph.D.
Co-founder and CSO at Shoreline Biome

Mark’s talk will present data that the combination of lysis, PCR design, long readamplicon, and database are key to identifying microbial strains that influence human health.

Dr. Mark Driscoll has led and supported teams launching transformative new sequencing innovations globally since 2000, including teams at 454 Life Sciences that launched the GS20, GS FLX, and the GS Junior Next Generation Sequencing systems. Mark has experience leading the development of hardware, software, informatics and reagents supporting transformative NGS technology advancements.  As a co-founder and CSO of Shoreline Biome, Mark has been instrumental in the development of their high throughput DNA preparation and rRNA amplicon NGS kits, including the first all-in-one 16S-23S long read Amplicon kit and 16S-23S database, that, in combination with the PacBio sequencing system, enables differentiation of closely related bacterial strains using high-throughput, long read rRNA gene sequencing. Dr. Driscoll received his Ph.D. in Biochemistry from the University of Rochester.

About Novogene:

As the world’s largest NGS service provider, Novogene offers research, pre-clinical and clinical scientists abroad array of sequencing and bioinformatics services, including whole genome and exome sequencing, targeted panel sequencing, RNA sequencing, single cell sequencing and microbiome sequencing, for a wide spectrum of sample types. To date, we have:
  • The largest sequencing capacity in the world with: 27-Illumina NovaSeq, 30-Illumina HiSeq X, 20-PacBio Sequels, 5 Thermo Fisher Ion S5XL, and more!
  • Completed nearly 20,000 projects
  • Sequenced 3,700,000 samples for more than 10,000 global customers
  • Analyzed more than 500,000 biological samples (in 2017 alone!)
  • Published over 1,850 customer research papers in top publications, like Nature and Science
  • Accumulated approximately 50 NGS-related patents

In addition, Novogene has developed and validated several clinical-grade oncology assays for precision medicine following strict quality control standards to ensure the highest data quality. These include:
  • NovoFocus™ NSCLC CDx – A CFDA-approved 26-gene companion diagnostic assay for patients with non-small cell lung cancer
  • NovoFocus™ PARPi CDx – An analytically validated 45-gene companion diagnostic assay for patients who may benefit from PARP inhibitor treatment
  • NovoPM™ - A ~500-gene comprehensive genomic profiling panel for solid tumors
  • NovoNeoantigen™ - A robust bioinformatics pipeline for cancer neo-antigens identification using whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples

Novogene is fully committed to helping you meet your drug R&D goals with our state-of-the-art sequencing facilities, unparalleled scale, efficiency, quality, and price.

About Shoreline Biome:

Shoreline Biome is a start-up company witha passion for developing innovative discovery technologies for the microbiomeand bringing these products to market.

Shoreline Biome has created discovery tools that are advancing the leading edge of understanding how the human microbiome functions across the entire landscape of human health and disease. The initial products from Shoreline Biome, are the first DNA sequencing assays to comprehensively, rapidly, and inexpensively identify all members of the microbiome down to the subspecies or strain level. These results are achieved through our superior cell breaking technology and rational product design. Our companion analysis software enables straight forward identification and quantitation of all of the bacteria in microbiome samples.

Event location: 1000 Massachusetts Ave,Cambridge, MA 02138

Event time: Time: 5:30pm-7:30pm,Thursday, April-18-2019
(Pizza will be served)

Please scan the QR code to register:
Thank you for the full sponsorship from Novogene!
































关于Z-Park中关村创新中心

Z-Park中关村创新中心 致力于搭建中美科技创新交流的桥梁, 中关村海外创新平台汇聚北美高精尖创新创业资源, 合作于众多知名投资基金、创业导师及学术专家,提供孵化加速、跨境培训、分析咨询为一体的专业服务。中关村帮助美国企业家和创业者在中国开拓市场,同时协助中国企业及投资者拓展海外业务,进行科学、合理合规的国际化战略规划。

旗下中关村硅谷、波士顿创新中心,位于美国创新创业资源两处核心地带,设有孵化器、共享办公空间、私人办公室、活动中心等多种功能空间,每年主办 200 余场技术分析会、学术讲座及创投活动,即吸引当地前沿技术和团队入驻孵化,又作为中国企业对外交流及拓展市场的软着陆点 ,是推动当地中美科技创新交流及产业化发展的重要交流中心。
关于青年学者联盟YSA

青年学者联盟YSA(Young Scholars Association)致力于打造青年学者的学术/工业交流平台,为广大青年学生学者服务。YSA希望聚集有志之士,上下求索,探未来之路 。欢迎扫描二维码关注YSA公众号!

如果读者有加入YSA青年学者交流群,欢迎扫码添加 YSA小助手为微信好友,有问题继续交流。请注明:加入YSA交流群

綠葉製藥Rykindo®有望成為我國首個在美獲批上市的創新藥

作為國家“重大新藥創制”科技重大專項之一,備受關注的自主研發新藥——注射用利培酮緩釋微球Rykindo®LY03004)已於美國東部時間328日,正式向美國食品藥品監督管理局(“FDA”)提交NDA新藥上市申請,有望成為我國首個在美獲批上市的創新藥。

綠葉製藥此次申報Rykindo®被業界視為一大里程碑,意味著公司投入多年的長效緩釋製劑研發平臺成功突破產業化瓶頸。這不僅是綠葉製藥全球化戰略中的關鍵一步,也是中國在全球製劑創新舞臺上邁出的一大步,受到各界廣泛關注。通過製劑開發、CMC及工藝優化、產能放大,註冊審評、商業化籌備等層層考驗,綠葉製藥已為Rykindo®及後續多個創新製劑的全球上市做好充分準備。

Rykindo®是綠葉製藥自主研發的緩釋微球製劑,以肌肉注射的方式每兩周給藥一次,治療精神分裂症和雙向情感障礙。此次提交的NDA新藥申請包含了一項關鍵性及兩項支持性臨床試驗的結果,共涉及172名美國病患。該項關鍵研究顯示:與利培酮長效注射劑的市場參照產品相比,首次注射Rykindo®後並無滯後期,且具有相等穩態藥代動力學。在所有三項研究中,Rykindo®與參照產品的安全性基本相似;在療效上,Rykindo®首次注射後三周毋須再服用口服製劑,且能更快達到穩態血藥濃度。Rykindo®上市後,可改善口服抗精神病藥物在精神分裂症患者中普遍存在的用藥依從性,每兩周給藥一次,將簡化精神分裂症的療程。

綠葉製藥預計,Rykindo®有望於2019年至2020年在美國和中國先後上市。與此同時,該新藥在歐盟和其他新興國家或地區的註冊也在同步順利推進中。

Rykindo®所處的中樞神經用藥領域,全球患者人群異常龐大且不斷增加。綠葉製藥在該治療領域進行的一系列佈局,將成為其下一階段業務增長的關鍵發力點。目前,公司已上市的中樞神經藥物包括:思瑞康及其緩釋片、卡巴拉汀單日貼片、芬太尼貼片、丁丙諾啡貼片等,這些產品覆蓋全球80多個國家和地區,包括中國、美國、歐盟、日本等主要醫藥市場,以及快速增長的國際新興市場。後續在研產品線中,另有注射用羅替戈汀緩釋微球(LY03003)、鹽酸安舒法辛緩釋片(LY03005)、帕利呱酮緩釋混懸注射劑(LY03010)、卡巴拉汀多日貼片(LY30410)等中樞神經新藥已在中國和海外同步進行開發。公司期待將更多優質創新的原研藥品帶給全球患者

綠葉製藥集團管理層表示:我們將全力推進Rykindo®在美國和中國的上市,並加速多個已處於NDA準備階段、III期及關鍵臨床階段的新藥的註冊進度。我們期待綠葉製藥能把更多優質創新的原研藥品帶給有需要的全球患者!”

Dr. Mien-Chie Hung, the president of CMU, will be in Boston to recruit overseas talent. It is a great opportunity to learn about upcoming faculty job opportunities in Taiwan!

In addition to clicking "going", please fill out the registration form if you are interested in attending: https://goo.gl/forms/bUXKEx9tdXMTduK33
  • Friday at 6 PM – 8:30 PM
    3 days from now3948°F Cloudy
  • Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston
中國醫藥大學招聘說明會
Time: 6pm-8:30pm, April 5th, 2019
Location: Room D1620, Dana-Farber Cancer Institute, 44 Binney Street, Boston
Agenda:
6:00pm-7:00pm Registration and Reception dinner 報到 & 晚餐
7:00pm-8:00pm Recruitment talk by Dr. Mien-Chie Hung 中國醫藥大學洪明奇校長攬才演講
8:00pm-8:15pm Q&A
8:15pm-8:30pm Introductino of MOST programs for overseas talents 波士頓科技組謝水龍組長介紹海外人才歸國橋接方案



2019 Boston BioForum

CABA 































Boston BioForum
May 4, 2019
波士顿生物医药论坛| CABA
Driving Transformation in Life Sciences Industry
ABOUT
The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and health- care fields to talk about hot topics in the Life Science industry. 
- Future of Immuno-Oncology
- Outlook of Cell & Gene Therapy
- AI & Big Data in Health
- Evolving Landscape for Life Science Investment
- Next Big Thing in Biotech & Pharma
Time & Location
Saturday, May 4, 2019 @ 9AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451


Confirmed Speakers
Will Brownsberger
 MA State Senator 


Jos Melenhorst    
Director, CAR-T Product Development
UPenn

Jonathan Terrett    
Head of Immuno-Oncology
CRISPR Therapeutics    

Sadik Kassim    
Executive Director
Kite Pharma    

Nenard Grmusa    
SVP, Head of External Innovation
Takeda    

Lei Xiao    
CEO
Innovative Cellular Therapeutics


Derrick Li    
Head of Strategy and Investor Relations
Cellular Biomedicine Group

Nick Valiante    
CEO
Glyde Bio    

F. Stephen Hodi    
Directot, Center for IO
Dana Farber Cancer Institute, Harvard Medical School

William Cao    
CEO
GraCel    

Rob Brainin    
CEO
NextCODE

Catherine Sabatos-Peyton  
Head of IO
Novartis    

Partial List of Sponsors from Past CABA Events 
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association

2019 SAPA-NE职业发展研讨会: Jump-Start Your Career!

SAPA-NE 美中药协SAPA
你想知道如何在职业生涯的不同阶段做出选择吗































你想了解求职中签证移民的准备策略吗?
你知道如何从导师那里受益吗?
你想成为一个更好的沟通者吗?
你想知道如何管理你的老板吗?
你想提升自己的领导能力吗?
你想拓展建立自己的社交网络吗?
你想拥有一张职场头像照片吗?

欢迎加入我们2019 SAPA-NE职业发展研讨会: 
Jump-Start Your Career!
3月30日上午10:00  - 下午6:00
Tufts University, Robinson Hall Room 252, 212 College Ave, Medford, MA, 02155
寻求指导, 分享智慧, 建立职业生涯。
Speakers
K.C. Donovan
Executive Director, DonoVision

Yaran Pan, LLM
Attorney at Law Office of Yaran Pan

Huijuan Li, Ph.D.
Head of Analytical Development, Moderna Therapeutics

Chen Cui, Ph.D.
Associate, McKinsey & Company

Peng Meng Kou, Ph.D.
Commercial Development Manager, MicroMedicine

Sumiao Chen, M.D., M.S.
Pharmacologist, Novartis Institute for Biomedical Research
CEO of SUMIAO XIANG restaurant

Dominic Yee, J.D., Ph.D.
Corporate Counsel, Sunovion Pharmaceuticals

Michael H Zhao, Ph.D.
CEO, Longwood Biology Inc.

★ Program ★
文字编辑:李科杰,梁雪,郭佳  微信编辑:李源涛


































Registration Is Now Open for Biotech's Can't Miss Event: BIO 2019
In just 4 months, 16,000+ biotechnology and global pharma leaders will come together for an exciting week of intensive networking to discover new opportunities and promising partnerships. We bring together a wide spectrum of life science and application areas including drug discovery, biomanufacturing, genomics, biofuels, nanotechnology and cell therapy.

Join the global biotech community to discover the next generation of cutting-edge products, innovation, therapies, and cures at events all week long.


BTBA Special Talk: National Taiwan University AI Center
Saturday, December 1, 2018 at 10:00 AM – 12:00 PM EST
MIT Building E25; Room 119/121
BTBA Special Talk: We are the honor to invite Dr. George Tseng to give us an introduction of National Taiwan University (NTU) - Artifical Intelligence (AI) Innovation Research Center. This NTU-AI center was founded in 2018 and under Taiwan's Ministry of Science and Technology (MOST; 科技部). The Center is composed of two sub-centers: 1). Artificial Intelligence Technology sub-center and 2). All Vista Healthcare sub-center. Please come to join us for enjoying this BTBA special talk to know the Technology development in Taiwan! 

BTBA 特別演講:這次我們邀請到台大人工智慧中心 (NTU-AI Center) 的曾柏元 副執行長,來跟大家介紹科技部在2018成立的台大人工智慧中心!此中心的全名為人工智慧技術暨全幅健康照護聯合研究中心,簡稱台大人工智慧中心或台大AI中心,包括智慧技術和生技醫療兩個主題、人工智慧技術及全幅健康照護兩個子中心。歡迎大家一起來聆聽並了解一下台灣目前的科技發展


著名的中医专家张季教授、中医科研专家李秀敏教授、中药颗粒剂专家天江药业总裁俞敏及Eric Brand博士将于11/11/2018莅临2018 哈佛中医药论坛暨天江中药配方颗粒学术论坛讲课。此次论坛将授予九个学分,收费(包括午餐)会员仅$60、非会员$90,哈佛Faculty, Fellow, Students 免费(需出示哈佛ID), 


ISCT publishes annual report on cell and gene therapy market authorisations

Report to enable patients and entire cell therapy community to identify treatments approved by government regulatory authorities

Vancouver, Canada, November 20, 2018 – ISCT, the International Society for Cell and Gene Therapy, the global professional society of clinicians, researchers, regulatory specialists, technologists and industry partners in the cell and gene therapy sector, today announces the first publication of its new annual report detailing global cell and gene therapies (CGT) with market authorization.

The CGT market authorization report is intended to provide a centralized resource and increased clarity for all of those involved in the CGT industry. This involves the scientific community, healthcare stakeholders and patient associations. The report will be a regularly updated document that will be republished yearly, and accessible through the ISCT website, www.celltherapysociety.org, and www.isct-unprovencellulartherapies.org.  

The report has been designed to react to the increase in momentum around a widening number of CGT authorizations, as well as a parallel increase of unproven approaches where cells are delivered as treatments without rigorous scientific and regulatory assessment and authorization. 

The report has been prepared by select members of the ISCT Presidential Task Force (PTF) on the Use of Unproven and/or Unethical Cell & Gene Therapies (UCGT) with lead authors Natividad Cuende (Executive Director, Andalusian Initiative for Advanced Therapies, Seville, Spain) and Laertis Ikonomou (Assistant Professor of Medicine, Boston University School of Medicine, Boston, MA). The ISCT Presidential Task Force was formed in 2014 to support ISCT’s ongoing commitment to address the rise of commercially available unproven or insufficiently proven CGT treatments. These approaches are targeted at hopeful individuals seeking cures or health improvement for a variety of conditions. The PTF-UCGT characterizes unproven cellular interventions and promotes safe and effective practices worldwide. 

The reliable, up-to-date resource will help patients to make informed decisions before receiving a CGT treatment so that they can avoid being exposed to unproven and unlicensed cell interventions not approved by a regulatory or medicine agency.

The report also provides an annual breakdown of CGTs that have received, as well in some cases, have withdrawn, market approval. This includes analysis on types of product and therapy as well as disease targeted. 44 unique products were identified. 84% were cell and tissue therapies, and 55% were autologous. More than one third target oncological or hematologic conditions. 

In the US, there are over 16 cell, tissue and gene products with marketing authorization, 14 in Korea, eight in Europe, four in India and Japan, two in Canada, and one each in China and Australia. This contrasts with Russia, Middle East, Africa, Central and South America, which have no CGT market authorizations or data available. 

“The number of market approved cell and gene therapy treatments continues to grow, with a high number of other therapies seeking approval. It is critical for all those involved in the sector, and most importantly those patients that may benefit from newly approved treatments, to have an annually updated resource detailing all approved cell and gene therapies,” said Massimo Dominici, Chair of the ISCT Presidential Task Force on Unproven and Unethical Cell & Gene Therapies. “This resource will give patients visibility on what cell and gene therapies have gone through proper approval processes, and help them alongside physicians to make more informed decisions about their treatment.”


In tandem with the efforts of professional societies like ISCT, it is imperative that the regulatory environment and guidance keep pace with the rapid advancements in cell and gene therapy. As such, this report also supports ISCT the FDA’s continued publication of numerous draft CGT guidance documents in 2018.

2018 Harvard TCM & Tianjiang Granule Extracts Forum
Time: 8:45am-6:00pm Sunday November 11, 2018
Place: Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont,
MA 02478
Parking: Free
CEUs (Continue Education Credit): 9 credits
Fee (lunch included): Members $60, none members $90
Free for Dr. Lee’s group, Harvard Faculty/Fellow (NO CEU, reservation
needed)
Sponsored: Massachusetts Society of Chinese Medicine (MSCM)
Alternative Medicine Center, McLean Hospital, HMS
Supported: Tianjiang Pharmaceuticals. CO.
Program
8:45-9:15am Registration
9:15-11:30am 七方理論臨床運用心得 张季
Experience in Clinical Application of Seven Formulas Theory dr.
Ji Zhang PhD, L.Ac
11:30-12:10pm Traditional Chinese Medicine, Western Science, and the Search
for a Cure for Allergies
Prof. Xiumin Li, MD New York Medical College
12:10-12:50pm 天江中药配方颗粒研究进展 俞敏 天江药业总经理
Progress on Tianiiang Granule Extracts Research Min Yu, CEO of Tiangjiang
Pharmaceuticals. Co.
12:50-2:10pm Lunch & discussion

2018 哈佛醫學院中醫藥論壇
暨天江中药配方颗粒学术论坛
2:10pm-2:40pm 配方颗粒的国际趋势:标准与临床特点 Eric Bran PhD
Global Trends in Granule Extracts: Standards and Clinical Styles Eric Bran
2:40-5:40pm 升陽益氣諸方劑在脾胃病的應用體會
Application Experience of Yang-raising and Qi-augmenting Formulas in
Spleen-Stomach Diseases Dr. Ji Zhang, PhD, L.Ac
5:40-6:00pm Discussion
Contact
Call Dr. Li 617 323 7809 or
Email:Johnzhang999@gmail.com
张季哈佛中医论坛講座簡介
1. 七方理論臨床運用心得
“七方“學說始見於《內經》。七方,即指大方、小方、緩方、急方、奇方,偶方、複方。歷代
醫家如金代張元素《醫學啟源》、張子和《儒門事親》、成無己《傷寒明理論》、明代李時珍《
本草綱目》均有闡發補充。國內各版高等中醫院校教材《方劑學》均認為“七方”為最早的方劑
分類法,臨床醫師多因其簡約古老而棄之不用;查閱中醫藥文獻,亦鮮見有關七方的理論與臨床
研究論文。而張季中醫師在臨床中體會到“七方“是指導臨床組方的利器,是提高臨床療效的法
寶,多年來鍥而不捨地研究“七方“理論的臨床應用,頗有心得。此次講座將結合臨床多個成功
案例分別加以詳細闡述。
2. 升陽益氣諸方劑在脾胃病的應用體會
胃腸道疾病在美國社會常見,與飲食不調和過重的精神壓力有密切關係,也有因長期使用西藥的
副作用而引發或加重。脾胃病為中醫之擅長。其治則不外疏肝解鬱,理氣止痛,益氣健脾,化濕
助運,活血化瘀,溫腎暖脾等等。但是對於一些疑難病症的治療,療效亦不甚滿意,張季中醫師
在脾胃病治療方面,宗金元易水學派張元素、李東垣等醫家的學說,在臨床中以臟腑標本虛實用
藥和升陽益氣、升陽除濕、升陽散火、升陽瀉濁法相結合,有一些體會,這次講座並將提供一些
治療成功的案例。
講員履历
張季,1978 年入學南京中醫藥大學中醫系,1983 年畢業後旋即留校任教,曾師從各家學說大家丁
光迪先生研究《諸病源候論》,碩士研究生期間又師從蜚聲海內外的《中醫學概論》、《中藥大
辭典》的主編吳貽谷導師,專攻中藥方劑的臨床應用,曾參加編寫《中華本草》《現代中藥學大
辭典》等10 餘部學術著作,其中多部獲獎。1992 年來美,又在美國獲DAOM 博士學位。張季中
醫師至今已在中美兩地臨床35 年,應用中藥方劑辨證施治,經驗豐富,對脾胃病、肝膽病、婦科
病、皮膚病的治療,特別是對過敏性疾病、感染性疾病和自身免疫性疾病的治療,頗有心得。自
1995 年起,先後執教於洛杉磯多家中醫院校碩士班和博士班。近年來,多次在美國各地中醫公會
講授再教育學分課程,並返回母校作多次學術演講,廣受好評。張季中醫師目前为世中聯內科專
業委員會理事、世中聯中醫藥推廣海外專家委員會委員、世中聯中藥上市後安全性再評估美國專
家委員會委員;并任南京中醫藥大學客座教授,南京中醫藥大學美洲校友會副會長,江蘇省中醫
院洛杉磯惠僑中心顧問。
俞敏,男,1973 年6 月出生,长江商学院EMBA 硕士,高级经济师,江苏省中药饮片研究专委会
常委副主委,现任江阴天江药业有限公司总经理。江阴天江药业有限公司成立于1992 年,隶属于
中国医药集团旗下中国中药控股有限公司。背靠中国医药集团这家中国规模最大、产业链最全、
综合实力最强的超千亿医药健康产业集团,天江药业及其中药配方颗粒产品致力于传承创新,以
优质中药产品和服务提升人民健康水平。天江药业是国内首家“全国中药饮片改革试点单位”,
首批“中药配方颗粒试点单位”,是中药配方颗粒行业的先驱者和领跑者。
俞总将详细介绍天江中药配方颗粒质量控制措施与机制,以及天江中药业配方颗粒生产工艺流程
Xiu-Min Li, M.D., M.S.. Dr. Li obtained her MD degree in Henan University
of Chinese Medicine (Zhengzhou) in 1983 and a Master’s degree in Clinical
Pediatric Immunology from The Graduate School of China Academy of
Chinese Medical Sciences (Beijing). She was a Visiting Scientist at Stanford,
and postdoctoral fellow in Clinical Immunology at Johns Hopkins (Baltimore)
where she was appointed instructor in 1997. She Joined the Division of
Pediatric Allergy and Immunology, Pediatric Department and was promoted
to Professor of Pediatrics with tenure at the Icahn School of Medicine at
Mount Sinai in 2009. She has combined expertise in immunology and
Chinese medicine. Her research has yield over 100 publications. She has trained over fifty
residents, clinical fellows, post-doctoral fellows, graduate students, medical students, and
visiting scientists. She has chaired prominent committees about the use of alternative medicines
for allergic diseases in the US and internationally. She recently joined Department of
Microbiology and Immunology as Professor and in the process to establish a Center of
Excellence for Clinical Immunology and Integrative Medicine. She was awarded the Future of
Health Technology Award for 2016. She is co-author of Traditional Chinese Medicine, Western
Science, and the Search for a Cure for food allergy with Henry Ehrlich.
Eric Brand is a licensed Chinese medicine practitioner with a passion for materia medica and
herbal quality discernment. After graduating from the Pacific College of Oriental Medicine in
2003, Eric spent over a decade pursuing academic and clinical opportunities in Taiwan, Hong
Kong, and mainland China. He earned his PhD at the School of Chinese Medicine at Hong
Kong Baptist University with a focus on Chinese herbal pharmacy, and he serves as a TCM
advisor to the American Herbal Pharmacopoeia. Eric has written or translated a variety of
modern and classical texts and peer-reviewed articles, and he served as Chair of the U.S.
delegation on the ISO Technical Committee for international TCM standards (ISO TC 249) from
2014 to 2017.

Welcome to the “1st International Conference on the Forefront of Complementary and Integrative Medicine,” which takes place at the Joseph B. Martin Conference Center of Harvard Medical School in Boston October 29-30, 2018. Please visit the website for more details: https://www.icfcim.com

2018年10月29-30日,哈佛大学医学院Josheph B Martin Conference Center  首届中西医替代及整合医学大会  最后一周注册机会!大会由哈佛医学院和北京中医药大学主办 Journal of  Phytomedicine ,麻州中医学会协办,届时世界顶级专家教授云集,包括哈佛医学院、NIH、斯坦福大学等十位著名教授李豫伟Thomas Efferth、北中医徐安龙校长,哈佛医学院结合医学系主任,NIH补充结合医学中心主任Helene Langevin,香港浸会大学中医学院院长吕爱平,香港中文大学中医药研究所所长梁秉中,北中医东方医院副院长林谦等。聆听中西医学发展前沿,领略名家风采,机会难得!对哈佛和MIT学生、Speaker 团队成员免注册费,提供会议午餐,但免费名额有限(签到时需提供学生或工作ID),请参会人员尽快注册https://www.icfcim.com/registration.html。




Saturday, September 8th
1:00 - 5:00 p.m. (EST)
Harvard School of Public Health 
Kresge G1
On-Site Judging Teams
Jessica Alderman Zeaske, Ph.D., MBA
Director, Healthcare Investments, GE Ventures
SU Lingyun
Director, Alibaba Health Research Institute
SHAO Qing
Senior VP at Porton;
Founder and Director, Beijing Bodun Chongde Charity Investments; Founder and Director of Network Think Tank;
Vice President, Moganshan Research Institute Expert Advisory Committee;
Vice Chairman, China Digital Assets Research Institute;
Director, United States Hope Investment Fund
Jing Ma, MD, PhD
Co-founder and Board Member, President, U.S.-China Health Summit; Director of China Center,
Associate Professor, Department of Population Medicine, Harvard Medical School
Kate (Xiaokui) Zhang
Senior Director, Global Bio-Therapeutic, Sanofi 
Shaan Gandhi, MD, MBA
Principal , Longwood Fund
Olivia Ho. Cheng
Board Member, U.S.-China Health Summit; CEO, Aurora Healthcare Corp.
Grannum R Sant, MD, FRCS, FACS
Professor and Former Chair of Urology and Urology Residency Program Director, Tufts University School of Medicine
ZHANG Rui
Partner, Lodestone Capital Partners
YANG Hailing
Senior Analyst, Decision Resources Group
Register to connect with judge panel right now!
More information? please visit: https://www.uschinahealthsummit.org/innovation
Any questions? Reach us at info@uschinahealthsummit.org
各位会员:好消息。著名医学气功专家北京中医药大学博导刘天君教授将于9/30/2018周日莅临哈佛中医药论坛授课!本次讲课包括现场带领大家练习。名额有限,先来先得。欢迎大家参加!请提前报名!谢谢!John Zhang
药明生物宣布投资6000万美元在美国新建生产基地

药明生物国际化战略再下一城
首次在美国布局生物制药生产基地

美国马萨诸塞州伍斯特市,中国上海,2018611——全球领先的开放式生物技术平台公司药明生物(WuXi Biologics, 2269.HK)今日宣布,公司计划投资6,000万美元(约合3.8亿人民币)在美国马萨诸塞州伍斯特市(隶属波士顿大都会区)新建现代化生物制药临床样品和商业化生产基地,并创造约150个工作岗位。

这是药明生物在全球范围布局的第十一个生产基地(药明生物十一厂),也是药明生物首次在美国新建生产基地,同时也是公司继爱尔兰、新加坡后投资建设的第三个海外生产基地。

药明生物为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,其使命是加快和转变生物制药发现、开发及生产,造福全球患者。

即将开建的药明生物美国基地将继续采用全球领先的一次性生物反应器,并率先应用“新一代生物制药生产技术”(连续生产工艺)开展商业化生产,致力于成为全球领先的生物制药“未来工厂”。该基地总产能将达到4,500升,包括22,000升流加细胞培养反应器与1500升灌流工艺生物反应器,基地建成后将拥有生物工艺开发实验室,并同时具备临床样品生产和小规模商业化生产的能力。此项目的推进得到了马萨诸塞州政府、伍斯特商业发展局(WBDC)和麻省生命科学中心(MLSC)的大力支持。

“马萨诸塞州拥有技术领先的公司、顶尖的学术机构和充满竞争力的人才,已经形成全球最具活力的生命科学创新生态系统之一。”马萨诸塞州州长查理·贝克(Charlie Baker)先生说,“我们很高兴药明生物选择在马萨诸塞州进行战略布局,更多企业的投资和快速发展将共同构建更加完整的创新生态系统。”

“这几天在伍斯特市与药明生物管理层的会见交流,让我深信他们将对这里的生命科学产业做出巨大贡献。”马萨诸塞州副州长卡琳·波利托(Karyn Polito)女士表示,“我们很高兴为伍斯特市生物医药产业园的发展而努力,我们将继续为各个领域的合作伙伴提供支持。”

“伍斯特市正在打造全新的生物医药产业园区,我们热烈欢迎药明生物成为首家选择入驻于此的企业。”伍斯特市政执政官Edward M. Augustus, Jr.先生表示,“作为全球生物医药市场中地位日益攀升的投资目的地,伍斯特市十分期待新园区的正式开幕,同时帮助药明生物的首个美国生产基地顺利落成。”

“我们很高兴药明生物选择了美国马萨诸塞州,更重要的是选择了伍斯特市。在马萨诸塞州贝克-波利托政府和伍斯特市政府的支持下,我们通过巨大努力最终促成了此项目成功落地。对伍斯特市而言,今天又是一个重要的日子。”伍斯特商业发展局总裁兼首席执行官Craig L. Blais先生表示。

麻省生命科学中心(MLSC)总裁兼首席执行官特拉维斯·麦克瑞迪(Travis McCready)先生表示,“我们很高兴见证药明生物在美国伍斯特市布局生产基地这一重大里程碑。药明生物全球领先的生物制药专业技术和能力将进一步巩固这里的生命科学创新生态系统,帮助马萨诸塞州的生物制药公司更迅速高效地开发创新疗法。我们将继续为此项目的顺利完成而努力。”

“波士顿大都会区是公认的世界生命科学领域的创新聚集地,药明生物的美国新基地在公司国际化战略中具有至关重要的作用,有助于确保公司生产的符合最高质量标准生物药,通过健全强大的供应链网络,造福全球患者。非常感谢美国马萨诸塞州各界人士对我们的大力支持,相信在大家共同的努力下,这个振奋人心的项目将迅速得到推进。”药明生物董事长李革博士表示。

药明生物首席执行官陈智胜博士表示:“我们非常高兴能在美国伍斯特市投建公司在美国的第一个生产基地,公司众多重要合作伙伴距离此基地车程仅2小时。新基地将有助于满足药明生物日益增长的生物制药开发及生产需求,从而更好地帮助当地合作伙伴加速生物药开发进程。药明生物致力于打造全球生物制药领域更宽、更广、更深的生物制药能力和技术平台,赋能当地及全球合作伙伴。”
关于药明生物
药明生物作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。如需更多信息,请访问:www.wuxibiologics.com.cn

WUXI BIOLOGICS TO INVEST $60 MILLION TO ESTABLISH A BIOLOGICS PRODUCTION FACILITY IN THE UNITED STATES

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United States
– WuXi Biologics’ first overseas site in the United States
2018/06/11
WORCESTER, MA and SHANGHAI, June 11, 2018 – WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that it is to invest $60 million and hire approximately 150 employees to establish a state-of-the-art biologics clinical and commercial manufacturing facility in Worcester, Massachusetts in the United States. The facility will be WuXi Biologics’ 11th global drug substance manufacturing facility (MFG11).
WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit patients around the world.
This state-of-the-art “facility of the future” will be built upon the novel approach that WuXi Biologics has pioneered in deploying single-use bioreactors. It is also designed to run continuous bioprocessing, a next-generation manufacturing technology to be implemented in America for the first time. A total of approximately 4,500 L bioreactor capacity will be installed with two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing. This facility will handle both clinical and small volume commercial production. An early-stage bioprocess development lab will also be included.
The new manufacturing facility supported by the Government of Massachusetts, the Worcester Business Development Corporation (WBDC) and the Massachusetts Life Sciences Center (MLSC), is the Company’s first overseas site in the United States, as well as the third outside China subsequent to Ireland and Singapore new sites.
“Massachusetts is home to one of the world’s most dynamic life sciences ecosystems, with leading companies, top-tier academic institutions, and a globally-competitive workforce,” said Massachusetts Governor Charlie Baker. “We are enriched when companies grow and invest here and are pleased to welcome WuXi Biologics’ expansion.”
“Having met WuXi Biologics’ leaders during their recent trip to Worcester, I am confident that they will contribute greatly to the city’s life sciences industry,” said Ms. Karyn Polito, Lieutenant Governor of Massachusetts. “I have been pleased to work on the development of Worcester Biomanufacturing Park and our Administration remains committed to supporting our public private partnership.”
“The City of Worcester is thrilled to welcome WuXi Biologics as its first tenant to the new Biomanufacturing Park,” said Worcester City Manager, Edward M. Augustus Jr.. “As a growing destination in the global biomedical market, the city looks forward to officially opening this impressive campus and is eager to host WuXi Biologics in their first US manufacturing facility.”
“We are delighted that WuXi Biologics has chosen the United States, Massachusetts, but most importantly Worcester. We competed very hard for this one and we prevailed. The Baker / Polito Administration and the City of Worcester stepped up to make this possible. Another great day for Worcester,” said Mr. Craig L. Blais, President and CEO of WBDC.
“We are excited to reach this important milestone on developing WuXi Biologics’ first US bio-manufacturing facility and to announce their intention to move to Worcester,” said Mr. Travis McCready, President and CEO of MLSC. “WuXi Biologics brings a global biologics manufacturing expertise that will enhance our life sciences ecosystem and help Massachusetts biopharma companies develop novel therapies quickly and efficiently. We look forward to continuing to work to finalize this project.”
“Metropolitan Boston is acknowledged as a leader in the biopharmaceutical industry. The new site plays a key role in WuXi Biologics’ global bio-manufacturing network to ensure that biologics are manufactured at the highest quality and within a robust supply chain to benefit patients worldwide. We are grateful for all the support local agencies and the talented people here have provided for us. We believe we can quickly push forward this exciting project,” said Dr. Ge Li, Chairman of WuXi Biologics.
Dr. Chris Chen, CEO of WuXi Biologics, added, “The new site will undoubtedly meet WuXi Biologics’ growing need for biologics development and manufacturing in the near future. Many partners of WuXi Biologics are located within two hours of this new site. We are all very excited to initiate our first US site to enable local companies and expedite biologics development in the United States. We are committed to becoming the most comprehensive capability and technology platform in the global biologics industry to enable both local and global partners.”
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.































20th SAPA-NE Annual Conference, Cambridge, MA, 

Jun 2-3

































Please Join Us to Discuss 
How Can We Save the Lives of
Patients, Our Family Members,
Our Neighbors, and Ourselves.

 
Overview
June 2nd
8AM – 6PM
Annual Conference
Tang Center, MIT
June 2nd
6PM – 9:30PM
20th-Anniversary Banquet
Boston Marriott Cambridge
June 3rd
9AM - 3 PM
Investment Forum
Boston Marriott Cambridge

 
Agenda
Helping Patients with Unmet Needs Through Innovation and Collaboration
June 2nd, 2018
8:00 AM – 6:00 PM
MIT, E51, Tang Center, Wong Auditorium
2 Amherst St, Cambridge, MA
8:00–9:00
Registration and Breakfast
9:00–11:55
Session 1: 
Patients with Unmet Needs Require New Treatment and Healthcare Innovation
11:55–13:00
Lunch and Exhibition
13:00–14:20
Session 2: 
Transformative Innovation Demands Novel Platforms
14:20–15:00
Coffee Break and Exhibition
15:00–16:40
Panel Forum:
Collaborations and Opportunities Across the Ocean
16:40–17:40
Session 3: 
Global Collaboration Drives Biomedical Innovation and Productivity
17:40–18:00
Closing Remark and Networking


SAPA-NE 20th Anniversary Celebration Banquet
(Biocytogen Night)
6:30 PM – 9:30 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
18:00–18:30
Networking
18:30–18:35
Welcome Remarks
18:35–19:10
Keynote Speech and Award
19:10–21:30
Dinner / Celebration


Biotech/HealthCare
Investment Forum
June 3rd, 2018
9:00 AM – 3:00 PM
Boston Marriott Cambridge
50 Broadway, Cambridge, MA
9:30–9:40
Opening Remark
9:40–11:20
Keynote Talks
11:20–12:00
Panel Discussion
12:00–13:00
Lunch
13:00–14:30
Roadshow Presentation
14:30–15:00
Conclusion


 
Invited Speakers
George M. Church, Ph.D.
Professor 
at Harvard & MIT
Dost Öngür, M.D.
Chief of the Psychotic Disorders Division, McLean Hospital
Shidong Jia, Ph.D.
Founder & CEO, Predicine Holdings Ltd.
Chris Garabedian
Chairman and CEO, Xontogeny
WilliamL. Fodor, Ph.D.
Acting CSO Biostage, Inc. 
Director Translational Sciences, Cell Therapy Group
Morris J. Birnbaum, M.D., Ph.D. 
SVP and CSO, Internal Medicine Research, Pfizer Inc.
Steve Yang, Ph.D.
EVP, CBO & CSO, WuXi AppTec
Yuelei Shen, Ph.D.
President and CEO,  Biocytogen Co Ltd.
Shenghong Steve Yang, Ph.D.
Manager, Sales and BD at Sino Biological US Inc.
Hong Cheng, Ph.D. & MBA  
Associate Vice President, Head of Research Strategy and Effectiveness for Global Research at Sanofi
Jin Li, Ph.D.
Chairman and CEO, HitGen
Yulian Zhang, Ph.D., MBA 
Executive Director, Kelun-Biotech Pharmaceuticals
Bill Liang, Ph.D.
CEO, CF PharmTech, Inc.
史文钊, Ph.D.
神州医疗科技股份有限公司总裁
Libing Yu, Ph.D.
Sr. Vice President, Business Development, Viva Biotech
Wenseng Wendy Pan, J.D. & Ph.D.
Partner, Sidley Austin LLP.

Ken Li, Ph.D.
Managing Partner, Yuanming Capital
Scott Zheng, MBA
Partner & CEO, SunForest Captital
Brad Loncar
CEO, Loncar Investments